Three Dividend Powerhouses Delivering $300 Annual Income on a $2,670 Investment

Want safe stocks that pay dividends while the market keeps you on edge? Here’s the reality: dividend-paying securities have crushed non-payers over the past 51 years, returning 9.2% annually versus just 4.31% for stocks that don’t distribute cash. Better yet, they’ve done it with less volatility than the S&P 500.

The trick is finding the right combination. We’ve identified three high-yielding picks that average 11.25% in annual returns — meaning a $2,670 portfolio split equally among them could generate roughly $300 in annual income.

AGNC Investment (NASDAQ: AGNC) — Yielding 13.28%

Start with mortgage REITs. AGNC Investment is one of them, and it’s currently offering a 13.3% yield with monthly payouts.

Here’s how it works: AGNC borrows money at short-term rates and uses those funds to purchase mortgage-backed securities (MBSs) that yield higher returns. When the Federal Reserve cuts interest rates, AGNC’s borrowing costs drop — this widens their profit margin and often boosts stock valuations. This is particularly relevant now as rate cuts create favorable conditions.

What makes AGNC a genuinely safe stocks that pay dividends? Look at the numbers. Of its $91 billion portfolio, $90.1 billion sits in agency MBSs — securities backed by the federal government. Only $700 million carries credit risk. This massive safety buffer allows AGNC to leverage capital effectively while maintaining a premium yield.

The math works because government backing reduces yields slightly but eliminates most default risk. When rates drop, the book values of these assets typically rise, and AGNC shares track closely to book value.

Pfizer (NYSE: PFE) — Yielding 6.87%

Pfizer represents the defensive dividend play. Yes, COVID drug sales have evaporated since their 2022 peak of $56 billion, crushing investor sentiment. But here’s what’s actually happening beneath the headlines.

The pharmaceutical giant grew total revenue 48% in five years — from $41.9 billion in 2020 to a projected $62 billion in 2025. That’s organic expansion far beyond COVID tailwinds. Their Seagen oncology acquisition is delivering 7% operating growth through mid-2025, signaling strong demand for cancer therapies and pricing power.

Add another layer: management expects $7.2 billion in cost synergies by end of 2026. Higher operational efficiency means fatter margins. Combine that with a forward P/E ratio of just 8, and you’re looking at one of the market’s cheapest pharmaceutical platforms — one that remains a safe stocks that pay dividends for conservative portfolios.

PennantPark Floating Rate Capital (NYSE: PFLT) — Yielding 13.61%

The third piece of this income puzzle is a business development company (BDC) that lends to middle-market companies.

PennantPark’s $2.77 billion portfolio is predominantly debt securities — specifically, variable-rate loans generating a weighted-average yield of 10.2%. Why so juicy? Middle-market firms lack access to traditional banking, so they accept higher rates.

The portfolio construction deserves attention: roughly 99% comprises variable-rate investments (meaning rates adjust with Fed policy), and over 99% represents first-lien secured debt (holders get repaid first if borrowers default). Average loan size sits at just $16.9 million, creating natural diversification.

Monthly dividends flow from this debt machine. Even as the Fed cuts rates gradually, PennantPark continues generating double-digit yields. The stock trades at a discount to book value, creating additional upside potential.

The Math: $300 in Annual Income

Split $2,670 equally ($890 each) into these three securities:

• AGNC delivers ~$118 annually at 13.28%
• Pfizer provides ~$61 annually at 6.87%
• PennantPark generates ~$121 annually at 13.61%
• Total: ~$300

The beauty of this safe stocks that pay dividends combination lies in the portfolio architecture: a government-backed mortgage REIT, a diversified pharmaceutical giant, and a secured-lending BDC. Each operates in different economic environments, yet all reward patient shareholders monthly or quarterly.

Before deploying capital, run your own due diligence. Yields can fluctuate, interest rate environments shift, and company fundamentals evolve. But for income seekers tired of chasing growth, this trio offers a tangible path toward steady, meaningful cash flow.